Isolated Central Nervous System Progression During Systemic Treatment With Brentuximab Vedotin Monotherapy in a Pediatric Patient With Recurrent ALK-negative Anaplastic Large Cell Lymphoma.
Adolescent
Anaplastic Lymphoma Kinase
/ analysis
Antineoplastic Agents, Immunological
/ therapeutic use
Brentuximab Vedotin
/ therapeutic use
Central Nervous System
/ drug effects
Central Nervous System Neoplasms
/ drug therapy
Disease Progression
Humans
Lymphoma, Large-Cell, Anaplastic
/ drug therapy
Male
Neoplasm Recurrence, Local
/ drug therapy
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
01 08 2021
01 08 2021
Historique:
received:
26
05
2020
accepted:
09
07
2020
pubmed:
10
8
2020
medline:
3
9
2021
entrez:
10
8
2020
Statut:
ppublish
Résumé
Central nervous system (CNS) involvement in anaplastic large cell lymphoma (ALCL) is uncommon. CNS prophylaxis is not regularly included in second-line treatments for patients who develop CNS-negative relapses. We report a pediatric case of recurrent ALK-negative ALCL who developed isolated CNS progression during the treatment with brentuximab vedotin monotherapy. The patient achieved CNS remission after receiving the CNS-directed treatments including craniospinal irradiation. There is no evidence regarding whether brentuximab vedotin can cross the blood-brain barrier. CNS prophylaxis should be considered in high-risk patients with relapsed ALCL who receive second-line treatments containing agents with limited CNS penetration.
Identifiants
pubmed: 32769561
pii: 00043426-202108000-00036
doi: 10.1097/MPH.0000000000001914
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Brentuximab Vedotin
7XL5ISS668
Anaplastic Lymphoma Kinase
EC 2.7.10.1
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e864-e866Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130:2709–2717.
Locatelli F, Mauz-Koerholz C, Neville K, et al. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin’s lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. Lancet Haematol. 2018;5:e450–e461.
Koga Y, Sekimizu M, Iguchi A, et al. Phase I study of brentuximab vedotin (SGN-35) in Japanese children with relapsed or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma. Int J Hematol. 2020;111:711–718.
Williams D, Mori T, Reiter A, et al. European Intergroup for Childhood Non-Hodgkin Lymphoma, the Japanese Pediatric Leukemia/Lymphoma Study Group. Central nervous system involvement in anaplastic large cell lymphoma in childhood: results from a multicentre European and Japanese study. Pediatr Blood Cancer. 2013;60:E118–E121.
Brugi’eres L, Le Deley MC, Rosolen A, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL group. J Clin Oncol. 2009;27:897–903.
Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30:2190–2196.
Mossé YP, Lim MS, Voss SD, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncol. 2013;14:472–480.
Mossé YP, Voss SD, Lim MS, et al. Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a Children’s Oncology Group Study. J Clin Oncol. 2017;35:3215–3221.
John TD, Naik S, Leung K, et al. Allogeneic hematopoietic cell transplant following crizotinib monotherapy for relapsed/refractory anaplastic large cell lymphoma. Pediatr Transplant. 2018;22:e13210.
Sekimizu M, Fukano R, Choi I, et al. Phase II Trial of CH5424802 (alectinib hydrochloride) for recurrent or refractory ALK-positive anaplastic large cell lymphoma. Blood. 2018;132(suppl 1):2924.
Brugières L, Quartier P, Le Deley MC, et al. Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children—a report from the French Society of Pediatric Oncology. Ann Oncol. 2000;11:53–58.
Mori T, Takimoto T, Katano N, et al. Recurrent childhood anaplastic large cell lymphoma: a retrospective analysis of registered cases in Japan. Br J Haematol. 2006;132:594–597.
Woessmann W, Zimmermann M, Lenhard M, et al. Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin–Frankfurt–Muenster (BFM)-type first-line therapy: a BFM-group study. J Clin Oncol. 2011;29:3065–3071.
Fukano R, Mori T, Kobayashi R, et al. Haematopoietic stem cell transplantation for relapsed or refractory anaplastic large cell lymphoma: a study of children and adolescents in Japan. Br J Haematol. 2015;168:557–563.
Abid MB, Wang S, Loi HY, et al. ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin. Ann Hematol. 2016;95:1725–1726.
Ruf S, Hebart H, Hjalgrim LL, et al. CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: a case series. Pediatr Blood Cancer. 2018;65:e27003.